Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The endothelial cell extracellular matrix (EC-ECM) is a complex, dynamic network of macromolecules secreted by endothelial cells to provide structural support and biochemical signaling [1]. It primarily consists of the basement membrane, containing collagen type IV, laminins, and heparan sulfate proteoglycans, and the interstitial matrix [2]. Beyond its role as a physical scaffold, the EC-ECM regulates critical vascular processes such as cell adhesion, migration, proliferation, and survival by interacting with cell-surface receptors like integrins [3]. In pathological states, the EC-ECM undergoes significant remodeling, contributing to tumor angiogenesis, atherosclerosis, and fibrotic diseases [4]. Therapeutic strategies often focus on specific components, such as oncofetal fibronectin variants or collagen-binding domains, to deliver drugs or inhibit pathological vessel growth [5]. For example, the L19 antibody targets the extra domain B of fibronectin, which is specifically expressed during neo-angiogenesis in tumors [6]. Additionally, fragments of ECM proteins like endostatin have been developed as anti-angiogenic therapies due to their ability to inhibit endothelial cell proliferation [7]. Understanding the composition and mechanical properties of the EC-ECM is essential for developing targeted therapies for cardiovascular and oncological conditions [8]. However, the ubiquity of ECM components in healthy tissues presents a significant challenge for achieving therapeutic selectivity and minimizing systemic toxicity [9]. Citations: [1] Slevin M, et al. (2009). J. Anat. [2] Yurchenco PD. (2011). Cold Spring Harb. Perspect. Biol. [3] Hynes RO. (2009). Science. [4] Lu P, et al. (2011). J. Cell Biol. [5] Neri D, Bicknell R. (2005). Nat. Rev. Cancer. [6] Schliemann C, Neri D. (2007). Drugs. [7] O'Reilly MS, et al. (1997). Cell. [8] Jarvelainen H, et al. (2009). Arterioscler. Thromb. Vasc. Biol. [9] Gkretsi V, Stylianopoulos T. (2018). Front. Oncol.
Inhibition of cell-matrix adhesion, blockade of growth factor sequestration, and disruption of ECM-mediated signaling pathways.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Endothelial cell extracellular matrix proteins (EC-ECM) (EC-ECM).